Effects of Sirolimus on disease progression in patients with Autosomal Dominant Polycystic Kidney Disease and severe renal insufficiency

Registry ID

EUCTR2007-005047-21

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

IST. DI RICERCHE FARMACOLOG. M. NEGRI

Start date

2007-12-24

Completion date

2012-07-16

Last update

2026-08-16

Conditions

• Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Summary

To compare the change over baseline of renal function (estimated by Delta GFR, measured by plasma iohexol clearance) in SRL and conventional treatment ADPKD patients with severe renal insufficiency (<40ml/min/1.73m2) after one year follow-up.

Locations

• , , Italy

Related clinical trials

• Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
• A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
• RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY
• Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease

View on source registry